Hematology/Oncology

Top Story

Curettage suggested as first treatment for tumorinduced osteomalacia lesions in long bone

September 3, 2015

As researchers of this retrospective study of 17 patients with tumor-induced osteomalacia lesions in long bones found 82% of tumors were located in the epiphysis, they recommend curettage as the initial surgical treatment followed by segmental resection in cases of incomplete resection or recurrence.

 “[Our] results suggest that multiple modalities of imaging may be needed to help localize the site of the phosphaturic mesenchymal tumor in a patient with tumor-induced osteomalacia,” the researchers wrote. “Curettage should be effective for most lesions near a joint, followed by segmental resection if needed.”

FDA News

FDA grants breakthrough therapy designation, priority review to Opdivo for nonsquamous NSCLC

September 3, 2015
The FDA granted breakthrough therapy designation and priority review to nivolumab for the treatment of patients with nonsquamous non–small cell lung cancer who…
In the Journals

Model helps predict long-term survival after surgery in patients with malignant mesothelioma

September 3, 2015
A prognostic model appeared to help predict long-term survival in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy, according to…
In the Journals

Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression

September 2, 2015
The telomerase inhibitor imetelstat demonstrates clinical activity in patients with myelofibrosis, according to the results of a pilot study.However, imetelstat (Geron…
Vitamin K antagonists do not affect bone mineral density, fracture risk In the Journals

Vitamin K antagonists do not affect bone mineral density, fracture risk

September 2, 2015
Vitamin K antagonists do not increase the risk for fracture or reduce bone mineral density, according to findings published in the Journal of Thrombosis and
More News Headlines »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Hematology Oncology Case Consults

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
morganatic-roan